<DOC>
	<DOCNO>NCT01832350</DOCNO>
	<brief_summary>The primary objective study test hypothesis Nuedexta ( 20/10 ) administer orally reduce Pseudobulbar Affect ( PBA ) frequency severity ( CNS-Lability Scale PLACS ) , satisfactory safety high tolerability patient Alzheimer 's Disease ( AD ) . The primary objective evaluate use study endpoint 1 , 13 , 26 week initiation treatment . The secondary objective study evaluate benefit treatment Nuedexta ( 20/10 ) cognition functionality demonstrate Rey Auditory Verbal Learning Test ( RAVLT ) , Trail make A B , Wechsler Memory Scale ( WMS ) logical memory delay recall , Controlled Oral Word Association ( COWA ) , Clinical Dementia Rating ( CDR ) , Neuropsychiatric Inventory ( NPI ) , Alzheimer 's Disease Cooperative Study Activities Daily Living Inventory ( ADCSADL ) 11-item Alzheimer 's Disease Assessment Scale-Cognitive subscore ( ADAS-Cog11 ) .</brief_summary>
	<brief_title>Nuedexta Treatment Pseudobulbar Affect Patients With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Quinidine gluconate</mesh_term>
	<criteria>Male/female 55 90 year , inclusive . Meets National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association criterion probable AD . Modified Hachinski Ischemia Scale score ≤4 . Folstein Mini Mental State Exam score 1626 Visit 1 . Geriatric Depression Scale score ≤6 . For patient history depression , he/she steady dose antidepressant least 3 month . Clinical history relevant symptom Pseudobulbar Affect . Center Neurologic StudyLability Scale score baseline ≥13 . Stable hematologic , hepatic , renal function , clinically significant symptom , clinical laboratory result ( CBC , clinical chemistry , urinalysis ) 1fold high upper limit normal range . Resting respiratory rate 1220/minute . MRI CT scan within past 12 month ; finding inconsistent diagnosis AD . ECG ( within 4 week prior entry ) evidence clinically significant abnormality . Concurrent treatment acetylcholinesterase inhibitor memantine allow ; must stable dose least 2 month screen . Dosing must remain stable throughout study . Use SSRI 's allow . Must use 3 month prior study entry ; dose must remain unchanged course study . No current symptom depressive disorder . Score 19 low Beck Depression Inventory . Agrees use prohibit medication study . Has current serious unstable illness , investigator 's opinion , could interfere analysis safety efficacy data ; life expectancy &lt; 2 year . No reliable caregiver frequent contact patient ( least 10 hours/week . Current prior history major psychiatric disturbance . Have clinical study within 30 day entry . Score 20 high Beck Depression Inventory . Multiple episodes head trauma , history within last year serious infectious disease affect brain , head trauma result protracted loss consciousness , myasthenia gravis . Within last 5 year , history primary recurrent malignant disease . Known sensitivity quinidine dextromethorphan . History human immunodeficiency virus , multiple severe drug allergy , severe posttreatment hypersensitivity reaction . History chronic alcohol drug abuse/dependence within past 5 year . Judged investigator serious risk suicide . Has recent current lab result indicate clinically significant lab abnormality . At Visit 1 ALT/SGPT value ≥2 time upper limit normal ( ULN ) ; AST/SGOT value ≥3 time ULN ; total bilirubin value ≥2 time ULN . Resting diurnal oxygen saturation &lt; 95 % . Received dextromethorphan quinidine within previous 6 month . Hypotension ( systolic BP &lt; 100 mm Hg ) ; postural syncope ; unexplained syncope . Used medication affect CNS ( except AD ) less 4 week . On disallowed concomitant medication . Experiencing acute exacerbation underlie neurological disorder within previous 2 month .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>